---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-178857"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-24T23:57:24.746760+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports positive retrospective data for AU-011 in choroidal melanoma vs. radiotherapy

## Summary
- Belzupacap sarotalocan showed statistically significant vision preservation at 2 years vs. plaque radiotherapy (logMAR p=0.0094).
- Radiotherapy patients lost ≥3 lines of vision in a majority by 2 years; ≥6 lines by 3 years.
- Data from 43 AU-011 patients vs. 150 matched radiotherapy controls (tumor edge within 3.0 mm of fovea).
- Mean follow-up for AU-011 was 15.6 months; study is retrospective and hypothesis-generating.
- Phase 2 trial (suprachoroidal) ongoing; pivotal trial expected to initiate by end of 2022.

## SEC filing metadata
- accession: 0001193125-22-178857
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312522178857/0001193125-22-178857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312522178857/d292968d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-178857
- JSON: https://secwatch.observer/filing/0001193125-22-178857.json
- Plain text: https://secwatch.observer/filing/0001193125-22-178857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.